Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study.
Vincenzo RussoAnna RagoRiccardo ProiettiEmilio AttenaCarmen RainoneMario CrisciAndrea Antonio PapaPaolo CalabròAntonio D'OnofrioPaolo GolinoGerardo NigroPublished in: BioMed research international (2019)
Dabigatran at the dose used for stroke prevention appears safer than VKA and maintains a similar efficacy profile, when used with DAPT, in AF patients who have undergone PCI with stenting for ACS.
Keyphrases
- atrial fibrillation
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- left atrial
- oral anticoagulants
- left atrial appendage
- direct oral anticoagulants
- prognostic factors
- heart failure
- percutaneous coronary intervention
- stem cells
- blood brain barrier
- st segment elevation myocardial infarction
- venous thromboembolism
- replacement therapy